Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932624 | 0.87 | S1PR1 (0.37) | FFAR4S1PR1SCN5ASCN9APGR | |
| SCHEMBL2089811 | 0.86 | FFAR4 (0.44) | FFAR4CHRM2CHRM1 | |
| SCHEMBL1993677 | 0.84 | PGR (0.44) | FFAR4S1PR1SCN5ASCN9APGR | |
| SCHEMBL475727 | 0.82 | PGR (0.43) | FFAR4S1PR1SCN5ASCN9APGR | |
| SCHEMBL4695771 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL16950420 | 0.77 | GRIN2B (0.42) | FFAR4 | |
| SCHEMBL16962097 | 0.77 | GRM5 (0.36) | GRM5EPAS1 | |
| SCHEMBL4693793 | 0.75 | GRM5 (0.42) | GRM5 | |
| SCHEMBL2160632 | 0.75 | GRM5 (0.42) | GRM5FFAR1 | |
| SCHEMBL23384797 | 0.75 | EPAS1 (0.45) | SCN5ASCN9APGRTRPA1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-105816453-B | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20200407316-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200131151-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-30 | — | — | US | disclosed |
| CN-104311472-B9 | Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives | 艾尼纳制药公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-104311472-B | Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives | 艾尼纳制药公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190135752-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20170217885-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9522133-B2 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-8415484-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| CN-102197038-A | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | ARENA PHARM INC | 2011-09-21 | — | — | CN | disclosed |
| CN-102164891-A | Substituted 1,2,3, 4-tetrahydrocyclopenta [ b ] indol-3-yl acetic acid derivatives useful for the treatment of autoimmune and inflammatory diseases | ARENA PHARM INC | 2011-08-24 | — | — | CN | disclosed |
| EP-2342205-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals ,Inc. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110130409-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2326621-A1 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2011005295-A1 | MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010011316-A1 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135752-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | FFAR4 30/4885S1PR1 1/4885SCN5A 1168/4885 |
| US-20110130409-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | FFAR4 26/4885S1PR1 1/4885SCN5A 1244/4885 |
| US-20170217885-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | FFAR4 26/4885S1PR1 1/4885SCN5A 1244/4885 |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | FFAR4 50/4885S1PR1 1/4885SCN5A 2664/4885 |
| US-20200407316-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | FFAR4 30/4885S1PR1 1/4885SCN5A 1168/4885 |
| US-20200131151-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | FFAR4 3697/4885S1PR1 1015/4885SCN5A 507/4885 |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | FFAR4 30/4885S1PR1 1/4885SCN5A 1168/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | FFAR4 30/4885S1PR1 1/4885SCN5A 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.